Clinicians making decisions about the treatment of individual patients need summary measures about therapies that derive from the best available evidence, and that can be readily extrapolated to clinical practice. The number needed to treat (NNT) refers to the number of patients that need to receive a therapy to prevent one bad outcome, or obtain one good outcome. The NNT is one of the most intuitive and clinically applicable metrics of effectiveness. Clinicians will more readily make sense of evidence that states its effect in terms of the NNT, than that expressed as a relative risk or an odds ratio. For a more detailed discussion of the advantages, limitations and clinical applications of common measures of therapeutic effect encountered in the literature, refer to a preceding companion review article. 1 ABSTRACT: Background: Numerous therapeutic interventions have been developed in the neurosciences. Clinicians need summary measures about efficacy of therapies that derive from the best available evidence, and that can be readily extrapolated to clinical practice. The number needed to treat (NNT) is intuitive and clinically applicable. We provide clinicians with a single source that summarizes important therapies in the main neurological and neurosurgical areas. Methods: Critically appraised evidence about therapies in the neurosciences was obtained from meta-analyses in all neurosciences groups in the Cochrane library, and from critically appraised topics at the University of Western Ontario. Therapies were included if they were deemed relevant and if outcomes were dichotomous. For each therapy, we obtained absolute risk differences and their 95% confidence intervals (CI), the corresponding NNTs, control and experimental event rates, and the time-frame of the outcome assessment. Results: We assembled a table of NNTs for 87 interventions in ten disease categories, deriving from meta-analyses (70%) or randomized controlled trials (30%), and assessing surgical interventions (7%), procedures (9%) or pharmacological treatments (84%). The NNTs varied widely, ranging from 1 in the use of epidural blood patch for post-dural puncture headache to 4608 for meningococcal vaccination. Preventative interventions had substantially larger NNTs. Time-frames were inappropriately short for many chronic conditions. Conclusions: Large collections of NNTs provide useful, updateable summaries of therapeutic effects in the neurosciences, an increasingly interventional clinical field.
METHODS
We used two approaches to find methodologically sound therapeutic research in the neurosciences. We searched the Cochrane database of systematic reviews (http://www. thecochranelibrary.com) for meta-analyses of interventions in all Cochrane groups with neurological or neurosurgical content (Back, Dementia and cognitive improvement, Depression, Anxiety and neurosis, Developmental psychosocial and learning problems, Epilepsy, Movement disorders, Multiple sclerosis, Musculoskeletal, Neuromuscular, Pain, and Stroke). Metaanalyses were included if one of the two authors (MB, SW) deemed them relevant for the neurosciences, if outcomes assessed were dichotomous and if they contained therapeutic information important for clinicians. We also used data from individual therapeutic trials previously assessed in the Evidence Based Neurology Programme at the University of Western Ontario and resulting in Critically Appraised Topics about therapy (http://www.uwo.ca/cns/ebn/). We included reports from 1986 to 2004. Priority was given to high-quality meta-analyses; individual randomized trials were included only when a metaanalysis was not available.
We obtained NNTs and 95% confidence intervals (95%CIs) for each intervention by computing the inverse of the absolute risk difference and its corresponding 95%CI. For data derived from meta-analyses, we used the Cochrane Library's default fixed effects model for pooling absolute risk differences. For consistency, all outcomes were expressed as positive events. The NNTs expressed the effect of treatment on improving the chance of the positive event, calculated as the inverse of the experimental event rate (EER) subtracted from the control event rate (CER).
For each intervention we reported the nature of the intervention, its comparator or control group, the specific outcome assessed, the time at which outcomes were assessed, the pooled control and experimental event rates, and the pooled NNT and its 95%CI.
RESULTS
In total, we included 87 therapeutic interventions in the following areas: Cognitive and behavorial disorders 5 (6%), Demyelinating disease 7 (8%), Epilepsy 20 (23%), Headache and pain 13 (15%), Infection 5 (6%), Movement disorders 5 (6%), Neuromuscular disorders 6 (7%), Neurooncology 2 (2%), Stroke and neurovascular disorders 20 (23%), Other disorders 4 (4%). Fifty-six (70%) interventions were derived from metaanalyses and 24 (30%) from individual randomized controlled trials. Two thirds of the interventions used a placebo control, whereas the comparator in the remaining third was an active control or comparison to usual or best medical therapy. Six (7%) were surgical interventions, 8 (9%) were procedures, and 73 (84%) were pharmacological treatments. The time of outcome assessment varied widely, ranging from 30 minutes (migraine therapy) to six years (stroke and neurovascular disorders). Twenty therapies, indicated in the Table by the presence of an asterix beside the relevant NNT, were not statistically beneficial by the NNT approach (95%CIs included infinitive or negative numbers [possibility of harm]). The NNTs also varied enormously across interventions, ranging from 1 in the use of epidural blood patch for post-dural puncture headache to 4608 for the meningococcal serogroup A vaccine.
DISCUSSION
The large number of interventions and NNTs compiled in this article attests to the transformation of the clinical neurosciences into highly interventional fields with very effective therapies. Several additional observations can be made about this collection of NNTs for neurological disorders. Relatively short time-spans for outcome assessment were used for some chronic neurological disorders, such as Epilepsy, Alzheimer's or Parkinson's disease. Longer outcomes provide more clinically meaningful information in chronic progressive disorders. There was a paucity of surgical or interventional data derived from RCTs. Only six reports pertained to these therapies, as compared to 73 medical interventions. Hopefully, the advent of numerous interventional and "miminimally invasive" procedures will be accompanied by a corresponding increase in robust evidence about their efficacy. As expected, preventative interventions required a much larger NNT than corrective or curative interventions. In the Heart Outcomes Prevention Evaluation (HOPE) study for example, 2 67 patients with hypertension and a previous stroke were treated to prevent a single stroke, whereas only three patients had to be treated with anticonvulsants to relieve neuropathic pain in one, 3 and seizures were controlled in one of every two patients that underwent temporal lobe surgery for epilepsy. 4 Because NNTs and other measures of effectiveness are meaningless in the absence of the time-frame when the outcome was assessed, we provided this information for each intervention. Clinicians dealing with patients whose outcome time-frame differs, can easily adjust the NNT to the desired timeframe, assuming that the relative effect of the intervention is more or less constant within the time-frame of interest. For example, the NNT for clinical improvement of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with steroids was 3.1 (95%CI 1.6, 199) at 12 weeks. 5 The NNT at 24 weeks can be calculated simply as follows: NNT S = NNT T x T / S, where NNT S = the NNT at the desired duration of follow-up (S) and NNT T = the NNT for the duration of followup in the trial (T). 1 In the above example, therefore, NNT 24 weeks = NNT 12 weeks x 12/24 = 3.1 x 0.5 = 1.6 (or 2, if we round upwards). That is, a longer period of observation results in a smaller NNT, assuming that the relative risk of the outcome event, and the relative effect of the intervention is constant over time. 1 The control event rate is also important for clinical application of the data in the Table. The baseline risk for events in our patients often differs from that in clinical trials. We can adjust the baseline risk to obtain an adjusted NNT. 1 For example, if an individual patient's risk of a poor outcome after cardiac arrest is felt to be twice that of patients enrolled in the trials assessing the effect of hypothermia, 6,7 the adjusted NNT is calculated as: NNT Patient = NNT Trial / F = 6.4 / 2 = 3.2, where F is the adjusted baseline risk of the individual patient. 1 That is, higher baseline risks result in lower NNTs. This assumes that the relative effectiveness of the intervention remains more or less constant across a range of baseline risks, an assumption that may not always be correct. Although these adjustments to NNTs make 1 First, NNTs are population, disorder, treatment and outcome specific. Therefore, direct comparisons across different disease conditions should be interpreted cautiously. Second, as described in the table, one must be mindful of the differences in follow-up time and baseline risk between patients involved in the index studies and those to whom one is applying the results. Methods to adjust for these at the bedside are described in an earlier companion paper. 1 Third, NNTs generated from meta-analyses are derived by pooling data from multiple trials and therefore must be interpreted with caution since the baseline risk, clinical setting, methodology and outcomes assessed may vary among trials included in the analysis. 88 Clinical variability among studies should always be considered and may be difficult to quantify. On the other hand, an assessment of statistical variability of results among studies (eg., heterogeneity) can be helpful in this regard. The majority of NNTs from meta-analyses reported in this article were derived from the Cochrane collaboration whose standard methodology includes estimates of statistical heterogeneity (using a chi-square analysis) prior to pooling of data from different trials. Fourth, since there is no clear threshold NNT at which specific therapies become worthwhile or worthless, some authors propose measures that encompass both the benefit and harm of an intervention, such as the "threshold number needed to treat". This approach aims to determine the magnitude of an NNT below which treatment is beneficial and above which treatment may be harmful. 89, 90 In this summary, we focused only on the beneficial effects of treatments, and not on their capacity for harm, often expressed as numbers needed to treat to harm (NNH). The evidence about harm is sparsely reported and poorly organized. Also, harmful effects of new interventions are often only appreciated after many patients have been treated in open label studies, often without controls. The reporting of harmful effects is a vast topic that requires a separate analysis.
Finally, it is transparent that any attempt to compile current evidence of therapies is obsolete by the time it is assembled, not unlike textbooks or monographs. However, in contrast to some traditional compendia and reviews, we have focused on sources of evidence that have been subjected to the rigour of critical appraisal and that can be updated as new evidence accrues. We hope that this compilation of estimates of the efficacy of various neurological therapies will be a useful tool for clinicians in the neurosciences looking to incorporate evidence based care into their practices. a = For consistency, all outcomes were expressed as positive events and NNTs as the effect of treatment on improving the chance of the positive event, calculated as the inverse of the experimental event rate (EER) subtracted from the control event rate (CER). b = The time range provided for meta-analyses was the range of the shortest and longest follow-up time of trials included in the analysis. c = Weighted pooled risk differences and NNTs from meta-analyses are provided, therefore these values may not correspond to ARRs and NNTs calculated directly from the control and experimental unweighted event rates. n = number of patients, * = not statistically significant, † = only generalizable to surgically-fit patients operated on by surgeons with complication rates <6%. Abbreviations: ACTH (adrenocorticotrophic hormone), ADAS-Cog (Alzheimer's Dementia Assessment Scale), ASA (acetylsalicylic acid), ARR (absolute risk reduction), CER (control event rate), CGI (Clinical Global Impression), CI (confidence interval), CBIC-Plus (Clinician's Interview-Based Impression of Change scale), EER (experimental event rate), GOS (Glasgow Outcome Score), NASCET (North American Symptomatic Carotid Endarterectomy Trial), NNT (number needed to treat), rhTPA (recombinant human tissue plasminogen activator), TIA (transient ischemic attack).
